Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion in cash, folding the three‑year‑old startup’s in vivo CAR‑T platform into its cell‑therapy pipeline. The deal, disclosed via BioCentury reporting, gives BMS access to Orbital’s lead OTX‑201 program aimed at reprogramming cells inside patients to treat autoimmune disease. In vivo CAR‑T delivers genetic payloads directly in the body rather than ex vivo manufacturing, promising simpler logistics but raising questions about delivery specificity and safety. Separately, the US Advanced Research Projects Agency for Health (ARPA‑H) awarded up to $41.3 million to Tessera Therapeutics to accelerate its in vivo CAR‑T efforts under the EMBODY program. ARPA‑H funding is intended to de‑risk in‑body cell engineering approaches and scale preclinical competencies. Together the acquisitions and awards underscore a rapid industry pivot toward in vivo modalities as big pharmas and funders chase lower‑cost, outpatient cell therapies.